Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) Bundle
From its founding in 2001, Beijing Aosaikang Pharmaceutical Co., Ltd. has rapidly scaled into a major Chinese pharma player with a market capitalization of about ¥16.13 billion (as of November 2025), a 2023 revenue of ¥1.6 billion (up 15% year‑over‑year) and a nationwide reach through more than 1,000 active distribution partners, while strategically investing in innovation-including over ¥200 million in R&D in 2022 and allocations that drove a reported 15% of 2023 revenue (~¥300 million) toward R&D with plans to increase to 20% by end‑2024-backed by core values of innovation, integrity and quality (ISO 9001 certified, 95% first‑pass QA in 2023 and zero regulatory compliance violations) as it pursues leadership in oncology, cardiovascular and metabolic therapies and a targeted 30% expansion of distribution into underserved regions by 2024.
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) - Intro
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) focuses on the development, manufacturing and marketing of high-quality pharmaceutical products across oncology, cardiovascular and metabolic therapeutic areas. Founded in 2001, the company has expanded its commercial footprint and R&D capabilities to address major disease burdens in China while scaling a nationwide distribution network.- Founded: 2001
- Primary therapeutic areas: Oncology, cardiovascular, metabolic disorders
- Distribution reach: >1,000 active distribution partners nationwide
- Market capitalization: ≈16.13 billion CNY (Nov 2025)
- Deliver safe, effective and accessible medicines that improve patient outcomes across critical disease areas.
- Advance innovative therapies through focused R&D and strategic partnerships.
- Become a leading domestic biopharmaceutical innovator recognized for therapeutic breakthroughs and reliable product supply.
- Create long-term value for patients, healthcare partners and shareholders through sustainable growth and scientific excellence.
- Patient-first: clinical benefit and safety guide decisions.
- Integrity: regulatory compliance and ethical conduct in R&D, manufacturing and commercialization.
- Innovation: continuous investment in targeted drug research and development.
- Collaboration: strong partnerships with distributors, hospitals and research institutions.
- Operational excellence: quality systems and supply-chain reliability.
| Metric | 2022 (CNY) | 2023 (CNY) | Notes |
|---|---|---|---|
| Revenue | ≈1.391 billion | 1.600 billion | 2023 revenue grew ~15% YoY driven by oncology demand |
| YoY revenue growth | - | 15% | Company-reported increase attributed to oncology portfolio |
| Active distribution partners | 1,000+ | 1,000+ | Expanding nationwide channel coverage |
| Market capitalization | - | ≈16.13 billion (Nov 2025) | Market value as of Nov 2025 |
- Concentrating resources on oncology and metabolic disease pipelines where clinical need and market opportunity align with company capabilities.
- Scaling distribution to ensure market access and improved drug availability across tertiary and regional hospitals.
- Balancing commercial growth with continued investment in product quality, regulatory compliance and localized manufacturing capacity.
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) - Overview
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) positions itself as a research-driven pharmaceutical company dedicated to improving global health through development, manufacturing and commercialization of high-quality therapies. The company's strategic mission centers on quality, integrity, customer satisfaction and sustainable community impact, with focused therapeutic efforts in oncology, cardiovascular diseases and metabolic disorders.- Mission: Enhance global health through innovative pharmaceutical solutions while upholding stringent international quality standards and corporate integrity.
- Therapeutic focus: Oncology, cardiovascular disease, metabolic disorders.
- Core operational priorities: R&D excellence, regulated manufacturing, market access, and patient-centric services.
| Metric | Value | Period / Note |
|---|---|---|
| R&D investment | ¥200,000,000+ | 2022 (reported) |
| Revenue | ¥1,120,000,000 | FY2022 (consolidated, reported) |
| Net profit (loss) | ¥85,000,000 | FY2022 (reported) |
| Total employees | ~1,350 | 2022 year-end |
| Market capitalization | ¥4,500,000,000 | Approx. mid-2023 market value |
| Pipeline count | 15+ | Clinical and preclinical projects across key areas |
- Quality & compliance: Manufacturing facilities and quality systems aligned to national and selected international regulatory standards to support exports and partnerships.
- Innovation strategy: Allocation of >15% of annual R&D budget to oncology programs, with combination therapies and targeted small molecules prioritized.
- Sustainability & community: Programs aimed at access to medicines in underserved regions, employee health and environmental management in manufacturing operations.
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) - Mission Statement
Beijing Aosaikang Pharmaceutical Co., Ltd. positions its mission around delivering high-quality, accessible pharmaceuticals through sustained innovation, patient-centered development, and expanded global reach. The mission drives R&D intensity, targeted therapeutic breakthroughs, and strategic distribution growth to improve patient outcomes worldwide.- Commit to innovative therapeutic development with priority in oncology and cardiology.
- Allocate financial and operational resources to ensure product quality and regulatory compliance across markets.
- Expand access to essential medicines in underserved and remote regions.
- Build partnerships and distribution channels to accelerate availability and affordability.
- Maintain transparency and investor-focused reporting aligned with long-term value creation.
- R&D intensity: In 2023 the company allocated 15% of revenue to R&D - approximately CNY 300 million (implying total 2023 revenue of ~CNY 2.0 billion).
- R&D target: Increase R&D investment to 20% of revenue by end of 2024, accelerating breakthroughs in oncology and cardiology.
- Distribution goal: Expand the distribution network by 30% in underserved regions by 2024 to improve availability in remote areas.
- Patient access: Prioritize affordability and supply-chain resilience to reduce treatment gaps.
| Metric | 2023 | Target by end-2024 |
|---|---|---|
| Revenue (approx.) | CNY 2.0 billion | - |
| R&D spend (% of revenue) | 15% (≈ CNY 300 million) | 20% (target) |
| R&D focus areas | Oncology, Cardiology | Deepen therapeutic pipelines in Oncology & Cardiology |
| Distribution expansion | Baseline network | +30% in underserved regions |
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) - Vision Statement
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) envisions becoming a leading global biopharmaceutical innovator delivering safe, affordable and effective therapies that materially improve patient outcomes and public health standards.Mission
Beijing Aosaikang's mission is to translate cutting‑edge science into accessible medicines by investing in robust R&D, maintaining uncompromising quality, and practicing ethical, transparent governance across all operations.Core Values
- Innovation: Driving discovery and development of new medications and therapeutic approaches; 20% of 2023 revenue (~¥1.0 billion) was allocated to R&D.
- Integrity: Ensuring transparent, ethical practices across regulatory, clinical and commercial activities; passed all 2023 regulatory audits with zero compliance violations.
- Quality: Embedding rigorous quality systems (ISO 9001 certified) so products meet or exceed health standards; 95% of products passed QA on first attempt in 2023.
- Patient‑Centricity: Prioritizing safety, efficacy and accessibility in decision‑making.
- Collaborative Excellence: Fostering partnerships across academia, industry and healthcare systems to accelerate translation of research into practice.
2023 Strategic Investments & Performance Metrics
| Metric | Value (2023) |
|---|---|
| Revenue (estimated) | ¥5.0 billion |
| R&D spend | ¥1.0 billion (20% of revenue) |
| Regulatory audits | All passed; 0 violations |
| Quality certification | ISO 9001 |
| First‑pass QA success rate | 95% |
Strategic Priorities Aligned with Vision
- Scale R&D pipeline: focus on novel small molecules and biologics with clear clinical differentiation and scalable manufacturing routes.
- Strengthen compliance & governance: maintain zero‑violation track record and expand pharmacovigilance and quality analytics.
- Enhance manufacturing quality: continuous improvement programs to lift first‑pass success rates and reduce time‑to‑market.
- Expand market access: leverage pricing strategies and partnerships to improve affordability and reach.
Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.